Microsaic Systems Share Discussion Threads

[jungmana] 19/12/2017 08:02

Top class appointment there :-)

[babbler] 19/12/2017 08:01

Look into thermo fisher imo.... GL.

[tomboyb] 19/12/2017 07:37

Morning -

That looks like a good appointment -

And the market looks like a positive start here today -

[guyswonga74] 19/12/2017 07:30

Market likes the news. Pre open 3.25/3.55

[jungmana] 19/12/2017 07:24

Good appointment there. Things are coming together nicely here.Market cap of just £6m right now with half that in cash. Just signed a deal with a big global pharma. Very undervalued today.

[moneymunch] 19/12/2017 07:24

Gearing UP for the Big Time. Gla ;-)

[jayj4u] 19/12/2017 07:17

Nice....I like the story!

[18bt] 19/12/2017 07:15

Very happy with Peter Grant's appointment - did excellent job at SKP.

[guyswonga74] 19/12/2017 07:09

Ducks being lined up on this very undervalued company

[guyswonga74] 19/12/2017 07:05

RNS out. New NED

[moneymunch] 19/12/2017 07:04

Microsaic SystemsDirectorate Change

RNS Number : 7196Z

Microsaic Systems plc

19 December 2017

 

19th December 2017

Microsaic Systems plc

("Microsaic" or the "Company")

Directorate Change

Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry ("MS") instruments designed to improve the efficiency of pharmaceutical R&D, is pleased to announce the appointment of Peter Grant MA (Oxon.), FCA to the position of Non-Executive Chairman, with effect from January 1, 2018.

 

Peter comes from a background in pharmaceuticals, electronics, engineering and financial services, where he has a successful track record of commercialising technology, high growth, turnarounds, working capital reductions and mergers and acquisitions. His skills and experience are expected to be particularly relevant to Microsaic as it progresses into the next stages of development.

Mr Grant has had an executive career spanning 40 years, nearly half at listed company board level, as CEO/CFO, including both London main market (up to FTSE 250) and AIM. His executive career included CEO of Skyepharma PLC, which, during his tenure, was transformed onto a strong growth path, CFO of Skyepharma PLC, Group Finance Director at Eurodis Electron PLC, Chief Financial Officer at WorldPay Group plc, Group Chief Executive at Molins PLC and Finance Director at Molins PLC. Prior to this he held a variety of senior commercial, financial and general management roles in the General Electric Company PLC group of companies.

Peter will chair the Finance and Audit Committee, and be a member of the Remuneration Committee of the Company.

Peter is Chairman of LiDCO Group Plc, Non-Executive Director and Chair of the Audit and Risk Committee of Abzena plc, and a Non-Executive Director of Labatec Pharma SA.

Eric Yeatman will step down as Interim Chairman of the Board with effect from 1 January 2018, and will remain a Non-Executive Director, Chairman of the Remuneration Committee, and member of the Finance and Audit Committee.

Glenn Tracey, CEO of Microsaic Systems plc, commented:

"We are delighted to welcome someone of Peter's calibre to the board as Chairman. We look forward to benefitting from the breadth of Peter's business experience and industry knowledge. I would like to take this opportunity to thank Eric Yeatman for acting as Interim Chairman since 31 January 2017."

Peter Grant commented:

"I am looking forward to joining such an innovative company and working with Glenn and the rest of the team to achieve Microsaic's potential. We will ensure that we have the right mix of skills and experience needed, have simple and transparent structures and importantly that we put our innovation and clients first."

Additional information on Mr Peter Grant

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

Peter William Grant (aged 62), holds or held the following Directorships or Partnerships in the past 5 years:

[babbler] 19/12/2017 06:45

Today will be a good day again imo...assuming no news...

[moneymunch] 19/12/2017 06:41

Q&A with Glenn Tracey Chief Executive Officer at Microsaic Systems PLC (LON:MSYS)
Microsaic Systems PLC (LON:MSYS) Chief Executive Officer Glenn Tracey caught up with DirectorsTalk for an exclusive interview to discuss the research agreement with a global biopharma partner, the meaning of a biopharmaceutical, the biologics market and why they are seeing the need for in-process mass spectrometry for biologics that perhaps they wouldn’t see for traditional drugs.



Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that?

A1: Yes, absolutely so I’ve got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture.

I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product.

So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can’t give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales.



Q2: Now, you touched on biopharmaceuticals in your last interview, can you explain to us what is a biopharmaceutical?

A2: Biopharmaceuticals represent one of the most promising frontiers in medicine, they are also known formally as biological medical products or biologics. I think one of the key things that sets them apart from, say, traditional drugs is that they’re produced by genetically-engineered cells such as yeast and bacteria, very much in the same way as a home-brew kit and that sets them apart from traditional chemical synthesis.

Biologics themselves, they’re composed of sugars, proteins, nucleic acids or a combination of substances or increasingly, and in the future, actually living cells and tissues so really quite incredible. They often actually large proteins, they’re very complex but specific structure and that structure is specifically designed to target disease. Their uses range from diseases like psoriasis through to oncology and perhaps the most famous of the latter is the highly-successful treatment for breast cancer, Trastuzumab or Herceptin. That was developed quite a while ago in 1998 by Genentech and UCLA but actually interestingly is now on the World Health Organisation’s list of essential medicines.

I think what really sets them apart, aside from how they’re made, is while there’s extremely good efficacy the biologics specificity also drastically reduces unwanted side effects or adverse drug reactions, ADR’s as we call them. It’s estimated that those cost the US alone in excess of $100 billion annually and I guess it’s a sad case that figure is driven through about 2 million instances of ADR’s per annum in the US and tragically 100,000 deaths. As a matter of fact, the Centre for Education and Research on Therapeutics has put a figure on this as being the fourth largest killer in the US, ahead of pulmonary disease, diabetes, Aids and pneumonia, so it really is quite significant.



Q3: Can you give us a bit more background on the biologics market?

A3: There is a whole wealth of published material out there actually, but I can draw on a recent report that Deloitte estimate that by about the year 2019, biologics revenue in itself is going to earn the pharmaceutical market about $400 billion. That represents about a third of the annual income of the pharma market and I think it’s especially interesting because the term ‘biologic̵7; was actually relatively unknown even twenty years.

I think to put that into perspective, I can draw on a recent interview with a chap called Andrew Skibo, he’s MedImmune’s Head of Global Biologics Operations and Engineering, he states that across the industry as a whole, there’s around $20 million worth of biopharma site installs either in planning or underway.

Now, if you consider the cost of a new biologics plant can range from anywhere from 1/10 to $0.5 million and take over 5 years to fully implement, you can see that pharma sees an appreciable return on what stands to be obviously a significant level of investment.

For Microsaic Systems, what that means is that obviously the new installs are very interesting to us as a multiple-unit opportunity, actually in both current and future biological installations and this represents our target market.



Q4: Why are you seeing the need for in-process mass spectrometry for biologics that you perhaps weren’t seeing for traditional drugs?

A4: I think that’s the key question and it really is where the true benefit of mass spectroscopy for bioprocessing to be seen and I think it’s quite a detailed response actually.

So, I often compare the two, the biologics and the traditional. If you look at traditional small molecule pharmaceuticals, they’ve got a comparatively simple structure, they’ve also got very well-defined production methods and what it means, in essence, is that these drugs are relatively insensitive to change.

The difficulty we see with biologics goes back to how these drugs are manufactured by cells and the drugs structure or complexity, they’re very large molecules often being 30,000 atoms in size versus 30 for a small traditional drug. The complex structure is very sensitive even for the smallest change in a host of different factors and these can include really anything from manufacturing parameters, differences in raw materials, storage. Even then, when you think you’ve got it defined, unwanted unknowns may introduce problems with the final product or actually with the still very high value intermediary products. Slight changes in structure of the biologic renders them useless or they can actually be potentially lethal and also, any harmful contaminates such as the remnants of the host cell protein can also cause a really nasty and often lethal immune response.

So, it’s really because of these risks that when the FDA grants their biologic licence to a biopharma company, they not only have to consider the product but also the process and the equipment so it’s really much wider than you would consider for a traditional drug. I think in recognition of this task, what the FDA does is to provide guidance of what it calls ‘Quality by Design’ or QbD and that covers four areas and these areas are actually very important for us. It covers four areas, that is the drug’s critical quality attributes to make sure that they meet key physical chemical and biological attributes of the drug itself. The second is that the drug companies identify the critical material attributes the incoming materials, the third is that the manufacturing process conforms to critical process and then that there is a relationship between that whole lot. In other words, basically what the FDA is saying is that things can’t be left to chance.

So, I suppose the punchline here is really what pharma is looking for is very much real-time, powerful analysis that’s needed in many access points across the process, in raw incoming goods, the upstream in sold drug production and downstream purification. All of these areas represent a potential commercial entry point for us, traditional technologies just don’t have the power for that sort of high structural confirmation I was just talking about.

What we’re doing is bringing our powerful detection both at at-line and on-line to provide immediate piece of mind. Just finally, we’re able to do that because we have a very unique all-in-one small footprint, in other words unlike contemporary mass spectrometry, we’ve got no need for cumbersome external pumps and external PC’s and it truly is a point of use mass detector with very easy maintenance and ease of use.

[miahkaysor] 18/12/2017 22:16

Keep an eye on ON-LINE (ONL) tomorrow, should spike to around £1.50 - £2.

[babbler] 18/12/2017 16:55

Yup. And they will want their money and then some imo. All good. 15% rise is excellent after Friday rise. Imo. closed above 3 too which is another sign. All coming together. Could erase all my losses elsewhere here imo.

[jungmana] 18/12/2017 16:40

Stock is very tightly held here. Most of the shareholders are institutions and directors from higher prices.The free float is about 40m only

[dave4545] 18/12/2017 16:27

Bottom fishing elsewhere and not doing too well but when they turn as what happened here your fortunes can improve rapidly.

[babbler] 18/12/2017 16:24

Lion managed it for over a week. Why not here imo?

[sigora] 18/12/2017 16:07

the peeps who got spiked last week will step of train here and there but the momentum is behind her

[jungmana] 18/12/2017 16:07

Great interview there by our CEO. Dave, if you happy with your profit why not. Well done